Bifidobacterium longum is a species of probiotic bacteria that is naturally found in the human gastrointestinal tract and vagina (1). It is a gram-positive, anaerobic bacterium that has been extensively studied for its potential health benefits. It is a vital component of the gut flora, and its ability to produce lactic acid is believed to inhibit the growth of harmful microorganisms. Bifidobacterium longum may play an important role in immunity, infections, candida infections, gut health, intestinal inflammation, and irritable bowel syndrome (2).
Bifidobacterium longum is a highly adaptable probiotic that can withstand harsh gut conditions. It remains resilient even when exposed to stomach acid, pH fluctuations, and the gastrointestinal tracts rigors, thereby aiding the gut by attaching to the intestinal lining and continuing through to the colon (1).
Bifidobacterium longum strains are predominantly present in infants and young children, frequently transmitted from the mother during natural delivery and breastfeeding. However, new-borns delivered via Caesarean section or fed with formula milk may lack this crucial bacterium and supplementation is recommended (1).
If you have a weakened immune system, please consult your health care practitioner before using this product.
Epigenetics probiotic Bifidobacterium longum is produced in a vegan friendly and convenient delayed release capsule. Recommended daily dose is 1 serving per day taken after a meal, or as directed by a healthcare practitioner. This product is not intended to be used as an alternative to a varied diet.
||Amount per serving
|Inulin (from Jerusalem artichoke)
||50 mg (5B CFU)
† Percent Daily Reference Intakes (RI) not established.
INGREDIENTS: Organic Jerusalem artichoke tuber extract (Helianthus tuberosus), Delayed release vegetable capsule (Hydroxypropyl methylcellulose, Gellan gum), Bifidobacterium longum.
Suitable for vegans
One of the most well-established benefits of Bifidobacterium longum is its ability to modulate the immune system. According to research, Bifidobacterium longum exhibits potential effects on the immune system by reinforcing the body’s defences against detrimental pathogens. In infants, Bifidobacterium longum has been observed to trigger the anti-poliovirus response and heighten their resistance to respiratory tract infections. For the elderly, Bifidobacterium longum is particularly significant as it has been demonstrated to enhance their immune system. Furthermore, in a study involving mice infected with influenza, Bifidobacterium longum was found to ameliorate symptoms, decrease mortality rates, and reduce inflammation in the lower respiratory tract (1).
Bifidobacterium longum may play a role in the gut microbiota. Certain strains of Enterotoxigenic Bacteroides fragilis (ETBF) have been linked to acute and persistent diarrhoea, inflammatory bowel disease, and colorectal cancer. However, Bifidobacterium longum has been shown to significantly decrease ETBF levels in humans. Likewise, In elderly patient receiving enteral feeding, Bifidobacterium longum was observed to modulate the intestinal environment and improve their general health. In mice, Bifidobacterium longum supplementation increased biotin levels produced by Bacteroides caccae and elevated Eubacterium rectale, a butyrate producer. Bifidobacterium longum was also found to maintain high Lactobacilli levels in mice and reduce endotoxins in rats when administered as Bifidobacterium longum ssp. Infantis. Additionally, Bifidobacterium longum ssp. Infantis was seen to increase propionic, succinic, and butyric acid levels in rats, highlighting the probiotics ability to positively modulate the gut microbiota (2).
Bifidobacterium longum ssp. Infantis, has been demonstrated to be effective in reducing intestinal inflammation and treating individual and global symptoms of irritable bowel syndrome (IBS) without any adverse effects. Studies have found that Bifidobacterium longum ssp. Infantis improved abdominal pain/discomfort, bloating/distention, and bowel movement difficulties in IBS patients, and a clinical trial involving women further confirmed the effectiveness of Bifidobacterium longum ssp. Infantis in alleviating multiple symptoms of IBS. In addition to IBS, Bifidobacterium longum has been found to ameliorate symptoms of ulcerative colitis in both Japanese patients and mice, along with Bifidobacterium longum subsp. Infantis. This bacterium has also been shown to reduce visceral hypersensitivity in mice with IBS and significantly decrease the visceral pain threshold pressure of the first pain behaviour and total number of pain behaviours in rats (2).
Overall, Bifidobacterium longum is a promising probiotic strain with a wide range of potential health benefits. While further research is needed to fully understand its mechanisms of action and clinical applications, it is clear that this bacterium plays an important role in promoting overall health and well-being.
Individuals with weakened immune systems may experience blood infections when taking certain probiotics. While this is a rare occurrence, it is important for those with weakened immune systems to consult with their healthcare provider prior to taking any probiotic, including Bifidobacterium longum (3).
Packaging: 60 capsules
Recommended daily dose, 1 serving taken after a meal.
Serving size: 1 capsule, Servings per container: 60
Store in a refrigerator out of reach and sight of children. Once opened, consume within 6 months.